Girgaum, India
Girgaum, India

Time filter

Source Type

MCLEAN, Va.--(BUSINESS WIRE)--Booz Allen Hamilton (NYSE: BAH) announced the opening of a new, expanded office in Charleston, S.C. which will function as a Digital Hub to support the rapid growth of the firm’s Digital Solutions business. The state-of-the-art, 75,000 square-foot facility offers a tech-forward, open and multipurpose floor plan designed to foster collaboration on mission-critical projects and deliver new levels of innovation for clients including the U.S. Department of Veterans Affairs (VA) and the U.S. Navy. This new facility complements the more than 30,000 square feet of office, lab and warehouse space the firm also holds in North Charleston primarily supporting the Navy’s Space and Naval Warfare Systems Center Atlantic. Booz Allen has been a leader in the Charleston community since the 1990s, and today employs more than 550 across Charleston and North Charleston and serves clients ranging from the U.S. Navy to U.S. Department of Veterans Affairs. The firm’s professionals in the region are experts in areas as diverse as Agile and DevOps to data analytics, cloud technology and systems engineering to logistics and cyber. At its newly expanded Charleston Digital Hub at Clements Ferry Road, the firm expects to expand from 310+ to 400+ employees by calendar year’s end to capitalize on the growing demand for its digital services. This latest expansion is projected to bring at least $10 million of new capital investment. That team supports the company’s work with the U.S. Department of Veterans Affairs (VA) Veterans Benefit Management System, using agile methodologies to transform the VA’s paper-intensive compensation and pension claims system to a web-based, paperless system. Today, the digital transition has decreased the backlog in claims for veterans’ benefits by 87 percent, and reduced the average wait time for a claim decision by 100 days. Digital Solutions offers clients an interconnected set of high-demand solutions to make enterprises work faster and more efficiently. “Within Digital Solutions, we are integrating emerging technologies, a deep understanding of our clients’ missions and our 100+ year consulting heritage to drive technology modernization and support user adoption,” said Gary Labovich, executive vice president, Digital Solutions leader, Booz Allen Hamilton. “The SPARC acquisition advances our Digital growth strategy by expanding the scale of our services to support our clients’ demand for transformative technology.” The Clements Ferry Road facility is one of five hubs within Booz Allen’s Digital Solutions Network which connects and unifies the firm’s 4,000+ Digital Solutions practitioners. To expand after its acquisition of the software services unit of SPARC in 2015, Booz Allen began construction on a new addition to the existing facility, but, in July 2016, the adjacent original building caught fire, causing extensive damage. In continuity with the construction schedule and client deliverables, the firm stayed the course, coordinating with clients to allow employees to work remotely and use temporary office space to remain fully operational. “We are excited to demonstrate our continued commitment to the Charleston community through the opening of our new client-focused Digital Hub with the intent to grow and develop local tech talent,” said Charleston-based Elizabeth Buske, vice president, Booz Allen Hamilton. “The facility will represent an R&D space that will allow us to build, test and refine enterprise software solutions alongside our clients. Through this process of collective ingenuity, our clients will reach solutions in real time and on budget, achieving efficiencies and cost savings at scale.” The opening of the firm’s new hub is part of the company’s continued investment in Charleston, and Vision 2020 – its plan to develop client solutions and drive transformational growth through investments in people, capabilities and markets. Booz Allen’s Digital Solutions work includes the creation of an optimized website with an automated online assistant for the Department of Defense Federal Voting Assistance Program (FVAP) that successfully helps U.S. citizens—including approximately 150,000 military members deployed to more than 150 countries worldwide—vote in federal elections. For more on the impact of our work, visit: BoozAllen.com/insights. In partnership with Booz Allen, Agracil, Inc. and Frampton Construction provided development and general contractor services and McMillan Pazdan Smith served as the primary architect of the new office space. Booz Allen Hamilton (NYSE: BAH) has been at the forefront of strategy and technology for more than 100 years. Today, the firm provides management and technology consulting and engineering services to leading Fortune 500 corporations, governments, and not-for-profits across the globe. Booz Allen partners with public and private sector clients to solve their most difficult challenges through a combination of consulting, analytics, mission operations, technology, systems delivery, cybersecurity, engineering, and innovation expertise. With international headquarters in McLean, Virginia, the firm employs approximately 22,800 people globally, and had revenue of $5.41 billion for the 12 months ended March 31, 2016. To learn more, visit BoozAllen.com.


News Article | May 18, 2017
Site: www.prnewswire.com

The Vice President, Global Library Relations is responsible for building deep and mutually beneficial relationships across the library community, particularly in the academic and research sectors. Jean will lead programs that leverage Elsevier's capabilities to deliver analyses to form the basis of collaborative discussions, develop systematic studies, form and lead projects that address mutual objectives, and facilitate knowledge transfer with and between Elsevier colleagues and librarians. "I'm really looking forward to the opportunity to be a communications conduit among librarians, researchers and Elsevier," stated Jean. "The scholarly arena is more intertwined than ever with the key need for all stakeholders to work together to shape an innovative future." Jean is a former president of the Medical Library Association (MLA) and past member of the Board of Directors for the Society for Scholarly Publishing (SSP). She also serves as Director, MidContinental Region and National Training Office, National Network of Libraries of Medicine. In addition, she is the Director for Information Transfer for the University of Utah's Center for Medical Innovation. She has served on advisory panels of the New England Journal of Medicine, The STM Association and SPARC, and has held many other professional offices and committee appointments. Dr. Michiel Kolman, Senior Vice President for Global Academic Relations at Elsevier, said: "Jean has a strong understanding of the global STM library environment and substantial experience at a senior level in library issues and challenges. She will forge connections and strategic alliances for Elsevier, helping library leaders worldwide achieve their aims." Jean has been active as a librarian throughout her career, graduating with a Master of Science in Library Science in 1980 and has been employed by the John Hopkins University, Greater Baltimore Medical Center, University of Maryland, University of Washington and Virginia Commonwealth University. An active author and editor, Jean is co-editing two forthcoming books: Information and Innovation: A Natural Combination for Health Sciences Libraries, and Strategic Collaborations in Health Sciences Libraries. Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com


News Article | May 18, 2017
Site: www.prnewswire.co.uk

The Vice President, Global Library Relations is responsible for building deep and mutually beneficial relationships across the library community, particularly in the academic and research sectors. Jean will lead programs that leverage Elsevier's capabilities to deliver analyses to form the basis of collaborative discussions, develop systematic studies, form and lead projects that address mutual objectives, and facilitate knowledge transfer with and between Elsevier colleagues and librarians. "I'm really looking forward to the opportunity to be a communications conduit among librarians, researchers and Elsevier," stated Jean. "The scholarly arena is more intertwined than ever with the key need for all stakeholders to work together to shape an innovative future." Jean is a former president of the Medical Library Association (MLA) and past member of the Board of Directors for the Society for Scholarly Publishing (SSP). She also serves as Director, MidContinental Region and National Training Office, National Network of Libraries of Medicine. In addition, she is the Director for Information Transfer for the University of Utah's Center for Medical Innovation. She has served on advisory panels of the New England Journal of Medicine, The STM Association and SPARC, and has held many other professional offices and committee appointments. Dr. Michiel Kolman, Senior Vice President for Global Academic Relations at Elsevier, said: "Jean has a strong understanding of the global STM library environment and substantial experience at a senior level in library issues and challenges. She will forge connections and strategic alliances for Elsevier, helping library leaders worldwide achieve their aims." Jean has been active as a librarian throughout her career, graduating with a Master of Science in Library Science in 1980 and has been employed by the John Hopkins University, Greater Baltimore Medical Center, University of Maryland, University of Washington and Virginia Commonwealth University. An active author and editor, Jean is co-editing two forthcoming books: Information and Innovation: A Natural Combination for Health Sciences Libraries, and Strategic Collaborations in Health Sciences Libraries. Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com


One of only eleven winners announced, FCA won in the manufacturing category for project SPARC (Sustainability Performance Analysis Reporting Compliance). "This year's award winners, including Fiat Chrysler Automobiles, were selected for their implementation of innovative EHS technology," said David Metcalfe, Verdantix CEO and chair of the Innovation Awards panel. "In an environment where many EHS managers describe themselves as technology laggards, we are pleased to see FCA's commitment to harnessing the power of innovative software to intersect people, processes, and technology to foster continuous improvement." "Digital transformation has had a profound impact on the EHS industry, presenting exciting opportunities and new challenges alike for EHS managers and organizations across industries," said Harold Gubnitsky, president at ProcessMAP. "Our work with FCA underscores the elevation of EHS as a core pillar of operational excellence, as well as the critical role of decision-ready intelligence – enabled by next-generation technology solutions – in achieving that imperative." Finalists were selected from a list of nominees and category winners were voted on by an independent judging panel. About ProcessMAP Corporation ProcessMAP Corporation is the industry's first enterprise data intelligence cloud software for Risk, Health, and Safety management, empowering organizations to protect people, assets, and profits. The company is headquartered in Sunrise, Fla., with locations across the globe, serving customers in over 125 countries. For more information, visit ProcessMAP.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/processmap-customer-fiat-chrysler-automobiles-wins-2017-verdantix-ehs-innovation-award-300463942.html


News Article | April 17, 2017
Site: www.techrepublic.com

Oracle SPARC systems are engineered from the cloud and provide customers with effortless security, breakthrough efficiency, and straightforward simplicity. “Cloud is the way to go and we try to deliver that in the form of a platform that you can rely upon, that can scale, scale massively, scale reliably. The thing about SPARC in contract to other chips is the software that runs on it is highly reliable. You can heat it, you can beat it, you can give it a lot of load, but it doesn’t break, it just keeps running.”


News Article | April 17, 2017
Site: www.techrepublic.com

Hear Masood Heydari, SVP of SPARC Engineering, discuss details of Oracle's servers designed for cloud and scale-out, which provide security by default, better core efficiency for cloud apps, and accelerate data analytics at X86 commodity cost points


CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) today provided an update on the timeline for the INTERCEPT Blood System for Red Blood Cells (RBCs) in Europe. The target timing for CE Mark submission has been extended, and the company’s European red cell study in chronic anemia patients has completed enrollment. Due to the need for additional time to complete quality control tests on the Chemistry, Manufacturing, and Control (CMC) registration lots required for regulatory submission, the company now plans to provide an update on new submission timing on its 4Q16 earnings call in early March. The CE Mark process for the INTERCEPT Blood System for Red Blood Cells includes review and approval by both TŰV SŰD as the Notified Body and Irish Health Products Regulatory Authority (HPRA) as the Competent Authority. Accordingly, a new submission filing date will need to be scheduled with TŰV SŰD Product Service GmbH. Cerus’ SPARC trial (A Randomized Controlled Study to Evaluate Efficacy and Safety of INTERCEPT Treated Red Blood Cells in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion) has now reached its enrollment target of at least 70 evaluable patients, and the company expects that study data will be available in time to support its anticipated European product launch. The SPARC study is being conducted in transfusion-dependent thalassemia major patients, an inherited blood disorder of abnormal hemoglobin resulting in excessive destruction of red blood cells. “Chronic anemia patients such as those with thalassemia major and sickle cell disease require more blood transfusions than almost any other patient group, putting them at elevated lifetime risk for exposure to existing and emerging pathogens,” said Richard Benjamin, Cerus' chief medical officer. “Our ability to provide safety and efficacy data generated by the chronic anemia study at the time of our anticipated product launch will be an important supplement to the clinical data already included for submission.” The SPARC study is a randomized, crossover trial in which patients receive two periods of transfusion support, consisting of one period each of conventional and INTERCEPT-treated RBCs over approximately 6 - 9 months in total. The primary efficacy endpoint is hemoglobin usage and the primary safety endpoint is immunogenicity. Hemoglobin usage was selected as the primary efficacy endpoint because it is correlated with the ability of transfused red blood cells to oxygenate tissues, persist in circulation, and suppress endogenous erythropoiesis. This endpoint is clinically relevant because hemoglobin consumption is correlated with iron burden, an important complication for patients despite availability of chelation therapies. Red blood cells are disc-shaped cells containing hemoglobin which deliver oxygen from the lungs to all body tissues. Red blood cells are the most frequently transfused blood component, with over 80 million units transfused globally each year. Patients typically receive red blood cell transfusions to offset blood loss after trauma and during surgery, or to increase hemoglobin levels in patients with hereditary anemia. ABOUT THE INTERCEPT BLOOD SYSTEM FOR RED BLOOD CELLS Cerus reported positive results of the INTERCEPT Blood System for Red Blood Cells from a European Phase III acute clinical trial in 2015. If approved, the INTERCEPT Blood System for RBCs will be the only system commercially available in Europe to enhance the safety of red blood cell transfusions through pathogen inactivation. In addition to plans to submit for CE Mark registration in Europe, Cerus is also currently in dialogue with the U.S. Food & Drug Administration regarding a protocol design for a Phase III pivotal red blood cell study to be conducted in the continental United States. Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See www.cerus.com for information about Cerus. INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation. Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements concerning Cerus’ plans to pursue CE Mark approval in Europe for the red blood cell system and the timing thereof; the potential for CE Mark approval for and commercial launch of Cerus’ red blood cell product in Europe; and Cerus’ plans to present data regarding the study results from its study in transfusion-dependent thalassemia major patients. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the uncertain and time-consuming regulatory process, including completion of all of the CMC activities necessary to support a regulatory submission; that Cerus may be unable to file for CE Mark approval of the red blood cell system in Europe in the anticipated timeframe or at all, and even if filed, that Cerus may be unable to obtain CE Mark approval, or any other regulatory approvals, of the red blood cell system in a timely manner or at all; Cerus’ belief that the results from its clinical trial will support its CE Mark submission, Cerus’ development of the INTERCEPT Blood System for red blood cells and its therapeutic potential, the risks associated with the uncertainty of clinical trial results, as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including in Cerus‘ Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 4, 2016. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.


News Article | December 15, 2016
Site: www.eurekalert.org

Considerable evidence has indicated that the drug metformin, used for more than 50 years to treat type 2 diabetes, also can prevent or slow the growth of certain cancers; but the mechanism behind its anticancer effects has been unknown. Now a team of Massachusetts General Hospital (MGH) investigators has identified a pathway that appears to underlie metformin's ability both to block the growth of human cancer cells and to extend the lifespan of the C.elegans roundworm, implying that this single genetic pathway plays an important role in a wide range of organisms. "We found that metformin reduces the traffic of molecules into and out of the nucleus - the 'information center' of the cell," says Alexander Soukas, MD, PhD, of the MGH Center for Human Genetic Research, senior author of the study in the Dec. 15 issue of Cell. "Reduced nuclear traffic translates into the ability of the drug to block cancer growth and, remarkably, is also responsible for metformin's ability to extend lifespan. By shedding new light on metformin's health-promoting effects, these results offer new potential ways that we can think about treating cancer and increasing healthy aging." Metformin's ability to lower blood glucose in patients with type 2 diabetes appears to result from the drug's effects on the liver -- reducing the organ's ability to produce glucose for release into the bloodstream. Evidence has supported the belief that this is the result of metformin's ability to block the activity of mitochondria, structures that serve as the powerhouse of the cell. But while that explanation appears to be fairly straightforward, Soukas explains, more recent information suggests the mechanism is more complex. Several studies have suggested that individuals taking metformin have a reduced risk of developing certain cancers and of dying from cancers that do develop. Current clinical trials are testing the impact of metformin on cancers of the breast, prostate and pancreas; and several research groups are working to identify its molecular targets. Soukas's team had observed that, just as it blocks the growth of cancer cells, metformin slows growth in C.elegans, suggesting that the roundworm could serve as a model for investigating the drug's effects on cancer. Their experiments found that metformin's action against cancer relies on two elements of a single genetic pathway - the nuclear pore complex, which allows the passage of molecules into and out of the nucleus, and an enzyme called ACAD10. Basically, metformin's suppression of mitochondrial activity reduces cellular energy, restricting the traffic of molecules through the nuclear pore. This shuts off an important cellular growth molecule called mTORC1, resulting in activation of ACAD10, which both slows the growth and extends the lifespan of C.elegans. In human melanoma and pancreatic cancer cells, the investigators confirmed that application of drugs in the metformin family induced ACAD10 expression, an effect that depended on the function of the nuclear pore complex. Without the complete signaling pathway - from mitochondrial suppression, through nuclear pore restriction to ACAD10 expression - cancer cells were no longer sensitive to the effects of metformin-like drugs. "Amazingly, this pathway operates identically, whether in the worm or in human cancer cells," says Soukas, who is an assistant professor of Medicine at Harvard Medical School. "Our experiments showed two very important things: if we force the nuclear pore to remain open or if we permanently shut down ACAD10, metformin can no longer block the growth of cancer cells. That suggests that the nuclear pore and ACAD10 may be manipulated in specific circumstances to prevent or even treat certain cancers." The essential contribution of ACAD10 to metformin's anticancer action is intriguing, Soukas adds, because the only published study on ACAD10 function tied a variant in the gene to the increased risk of type 2 diabetes in Pima Indians, suggesting that ACAD10 also has a role in the drug's antidiabetes action. "What ACAD10 does is a great mystery that we are greatly interested in solving," he says. "Determining exactly how ACAD10 slows cell growth will provide additional insights into novel therapeutic targets for cancer and possibly ways to manipulate the pathway to promote healthy aging." Lianfeng Wu, PhD, of the MGH Center for Human Genetic Research (CHGR) is lead author of the Cell paper. Additional co-authors are Ben Zhou, PhD, Christopher Webster, PhD, Michael Kacergis, MS, and Michael Talkowski, PhD, MGH CHGR; Noriko Oshiro-Rapley, PhD, Fan Mou, PhD, and Christopher Carr, PhD, MGH Department of Molecular Biology; Man Li, PhD and Bin Zheng, PhD, MGH Cutaneous Biology Research Center; and Joao Paulo, PhD and Steven Gygi, PhD, Harvard Medical School. Support for this study includes NIH grants R03DK098436, K08DK087941, R01DK072041, and R01CA166717, a Broad Institute SPARC Grant, and the Ellison Medical Foundation New Scholar in Aging Award. Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2016 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."


News Article | December 7, 2016
Site: www.PR.com

Global Service robotics market is expected to reach $34.7 billion by 2022, with a CAGR of 23.9% from 2015 to 2022, according to a new report by published by Allied Market Research. Portland, OR, December 07, 2016 --( Increasing need for safety along with government regulations for labor protection drives organizations to adopt service robotics for enhanced safety at workplace. The growing penetration of mobile devices facilitates the development of advanced robotic systems and boosts the growth of market. Vendors in the market focus on developing affordable and energy-efficient robots for small and medium enterprises to cater to the growing requirements of consumers. The significant rise in investments in R&D for the development of service robots along with the establishment of organizations including Standardized Procedures for the Advancement of Robotic Combat (SPARC) and International Federation of Robotics (IFR), further fosters the growth of the market. View more details of the report at: https://www.alliedmarketresearch.com/service-robotics-market Europe dominated the global service robotics market in 2014 in terms of revenue and is expected to maintain its dominance during the forecast period owing to the high demand of service robots from domestic, healthcare, and defense sectors. However, LAMEA is expected to exhibit highest growth in revenue, at a CAGR of 26.6% during the forecast period. Professional service robots are used in healthcare; defense, rescue, and security; field; logistics; and construction industries. The segment of professional service robotics generated $3.9 billion in 2014 owing to high demand of automation from these sectors. Reduction in labor costs, increased operational efficiency, and delivery of high-quality services with improved precision and accuracy further encourages consumers to employ professional service robots. The revenue of personal service robotics segment is expected to grow at a rate of over 26% during the forecast period, owing to high demand of service robots from the domestic and entertainment sectors and rise in disposable income of consumers. In terms of volume, personal robots accounted for a higher share and generated over 4,672 thousand units in 2014. Healthcare is the major end user industry, in terms of revenue generation, that employs service robots for a wide range of applications such as surgery, diagnostics, physical and mental therapy, and prosthetics among others. Patient monitoring, laboratory automation, drug discovery, and prescription preparation are other applications of service robotics in the healthcare sector. It accounted for over 35% share of the global market revenue in 2014, followed by defense, rescue and security sector. Other industries utilizing service robotics include field, logistics, construction, domestic, and entertainment. The construction industry is likely to grow at the highest CAGR during the forecast period. In terms of volume, defense, rescue, & security robots accounted for the highest share and generated around 11 thousand units in 2014 owing to the increased employment of unmanned aerial vehicles, unmanned ground vehicles, firefighting & disaster management robots, professional surveillance robots, and demining robots. The healthcare segment is forecast to grow at the highest CAGR of 29.1% during 2015-2022 in terms of volume. Key findings of Service Robotics Market: 1. The service robotics market is projected to exhibit a significant growth owing to increasing demand of automation from various industries, rising application areas, and growth in emerging economies. 2. The professional robotics segment is anticipated to dominate the market in terms of revenue owing to the increasing applications from healthcare, defense, rescue and security, agriculture, logistics, and construction industries. 3. The healthcare industry is excepted to maintain its leading position in the market during the forecast period in terms of revenue. 4. Europe is likely to dominate the market throughout the forecast period. Prominent players offering service robotics solutions in the market include iRobot Corporation, Intuitive Surgical, Inc., Honda Motor Co., Ltd., Panasonic Corporation, and Aethon Inc. These players introduce new products to enhance their portfolios and collaborate with each other to strengthen and expand their market and geographical presence. Portland, OR, December 07, 2016 --( PR.com )-- The growing need of automation across various industries has encouraged organizations to adopt service robotics for increased productivity, superior quality and precise operations, reduced operation costs, and enhanced safety of workforce.Increasing need for safety along with government regulations for labor protection drives organizations to adopt service robotics for enhanced safety at workplace. The growing penetration of mobile devices facilitates the development of advanced robotic systems and boosts the growth of market. Vendors in the market focus on developing affordable and energy-efficient robots for small and medium enterprises to cater to the growing requirements of consumers. The significant rise in investments in R&D for the development of service robots along with the establishment of organizations including Standardized Procedures for the Advancement of Robotic Combat (SPARC) and International Federation of Robotics (IFR), further fosters the growth of the market.View more details of the report at: https://www.alliedmarketresearch.com/service-robotics-marketEurope dominated the global service robotics market in 2014 in terms of revenue and is expected to maintain its dominance during the forecast period owing to the high demand of service robots from domestic, healthcare, and defense sectors. However, LAMEA is expected to exhibit highest growth in revenue, at a CAGR of 26.6% during the forecast period.Professional service robots are used in healthcare; defense, rescue, and security; field; logistics; and construction industries. The segment of professional service robotics generated $3.9 billion in 2014 owing to high demand of automation from these sectors. Reduction in labor costs, increased operational efficiency, and delivery of high-quality services with improved precision and accuracy further encourages consumers to employ professional service robots. The revenue of personal service robotics segment is expected to grow at a rate of over 26% during the forecast period, owing to high demand of service robots from the domestic and entertainment sectors and rise in disposable income of consumers. In terms of volume, personal robots accounted for a higher share and generated over 4,672 thousand units in 2014.Healthcare is the major end user industry, in terms of revenue generation, that employs service robots for a wide range of applications such as surgery, diagnostics, physical and mental therapy, and prosthetics among others. Patient monitoring, laboratory automation, drug discovery, and prescription preparation are other applications of service robotics in the healthcare sector. It accounted for over 35% share of the global market revenue in 2014, followed by defense, rescue and security sector. Other industries utilizing service robotics include field, logistics, construction, domestic, and entertainment. The construction industry is likely to grow at the highest CAGR during the forecast period. In terms of volume, defense, rescue, & security robots accounted for the highest share and generated around 11 thousand units in 2014 owing to the increased employment of unmanned aerial vehicles, unmanned ground vehicles, firefighting & disaster management robots, professional surveillance robots, and demining robots. The healthcare segment is forecast to grow at the highest CAGR of 29.1% during 2015-2022 in terms of volume.Key findings of Service Robotics Market:1. The service robotics market is projected to exhibit a significant growth owing to increasing demand of automation from various industries, rising application areas, and growth in emerging economies.2. The professional robotics segment is anticipated to dominate the market in terms of revenue owing to the increasing applications from healthcare, defense, rescue and security, agriculture, logistics, and construction industries.3. The healthcare industry is excepted to maintain its leading position in the market during the forecast period in terms of revenue.4. Europe is likely to dominate the market throughout the forecast period.Prominent players offering service robotics solutions in the market include iRobot Corporation, Intuitive Surgical, Inc., Honda Motor Co., Ltd., Panasonic Corporation, and Aethon Inc. These players introduce new products to enhance their portfolios and collaborate with each other to strengthen and expand their market and geographical presence. Click here to view the list of recent Press Releases from Allied Market Research


News Article | December 20, 2016
Site: www.prweb.com

Charleston, South Carolina – The Charleston Digital Corridor, along with title sponsor Charleston County Economic Development, is pleased to announce the 2017 Innovators’ 5k (iFiveK) will be held at Riverfront Park in the City of North Charleston on April 13th, 2017 at 6:30pm. Proceeds from this annual race benefit the Digital Corridor’s CODEcamp scholarships and other education programming. Confirmed sponsors include Charleston tech companies BoomTown, Blackbaud, Benefitfocus and Google. “Charleston County Economic Development is honored to be the title sponsor for the 2017 iFiveK. We value our partnership with the Charleston Digital Corridor and our aligned efforts to foster growth in our local tech industry including support of hands-on learning opportunities like CODEcamp,” said Steve Dykes, Executive Director of Charleston County Economic Development. In addition to our returning sponsors, we are pleased to welcome the first of several new sponsors for 2017 – Atlatl Software and Snagajob. “Atlatl Software is proud to sponsor the iFiveK for the first time this year. We’re excited to support an event that brings our tech community together with the proceeds going directly to CODEcamp, an invaluable program that teaches adults and kids the fundamentals of web development while fostering innovation and a passion for technology in Charleston,” said Marc Murphy, CEO of Atlatl Software. The iFiveK has become a favorite athletic and networking event for Charleston’s tech community. As one of only a handful of evening weekday races in the region, the iFiveK historically sells out well ahead of the event. For 2017, the Charleston Digital Corridor has refreshed the iFiveK logo and branding and launched a new modernized, mobile-responsive website that enables race participants to register on the run. Registration for the iFiveK officially opens January 1, 2017. “It is awesome to see our tech community come together for a fun evening of competition and networking while supporting the further development of talent in Charleston,” said Digital Corridor Director, Ernest Andrade. “We're passionate about supporting Charleston's tech community, and the iFiveK gives us the opportunity to celebrate the hardworking, competitive and fun atmosphere that drives so many successful companies here, and put that culture to work for important initiatives," said Grier Allen, CEO & President of BoomTown. Additional committed sponsors for the 2017 iFiveK include eGroup, SPARC, CarePoint, Bibliolabs, Immedion, and local microbreweries Holy City Brewing and Cooper River Brewing Company. About: Innovators' 5K (iFiveK): The iFiveK is an annual event that brings together Charleston’s tech community for an evening of spirited competition and networking. Proceeds from the iFiveK support CODEcamp scholarships and other education programming. More: ifivek.com Charleston Digital Corridor: The Charleston Digital Corridor is a community-sourced initiative to attract, nurture and promote the regions tech economy through an array of impactful programs, products and events while leveraging Charleston’s renowned livability. More: charlestondigitalcorridor.com

Loading SPARC collaborators
Loading SPARC collaborators